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ABBREVIATIONS:
experience symptoms of wheezing, shortness of breath, chest tightness, and cough 2 . Due to these 33 symptoms, asthma imposes a significant burden on patients, including increased morbidity, 34 mortality, and reduced quality of life 3 . Patients with asthma use more medications, and have 35 higher rates of hospitalization and physician visits than subjects without asthma 4 . The excess 36 direct medical costs of asthma are estimated to be $1,058 (2013 Canadian dollars) per person-37 year in British Columbia (BC) 5 . Thirteen percent of these costs were directly attributable to 38 asthma, and the majority (74%) of attributable costs were due to asthma-related medication use 5 . 39
Multiple evidence-based guidelines, including from the Global Initiative for Asthma, 40 recommend the diagnosis of asthma be confirmed by objective tests demonstrating either 41 reversible airflow limitation or increased airway hyperresponsiveness 2, 6 . Despite these 42 recommendations, studies suggest that asthma is diagnosed solely based on symptom history in 43 over half of physician-diagnosed cases 7, 8 . A recent population-based study in Canada found that 44 one in three patients with physician-diagnosed asthma did not meet the guideline-recommended 45 criteria for asthma diagnosis and could have their medications safely stopped 9 . These 46 'misdiagnosed' patients are likely imposing costs to the healthcare system due to treatment for a 47 condition that does not exist, and due to untreated underlying illnesses, which in some cases are 48 very serious 9 . By some estimates, there are over 785,000 misdiagnosed patients in Canada 49 alone 10 . 50
In response to these findings, some authors have called for population-based screening to 51 re-evaluate previous diagnoses of asthma 9, 10 . Assessing the value of these programs requires 52 precise estimates of the burden of misdiagnosed asthma on the healthcare system. However, 53 estimates of the cost differences between misdiagnosed and confirmed cases of asthma currently 54 do not exist. Characterizing the patterns of healthcare resource use among patients with 55 misdiagnosed asthma can help identify opportunities for re-evaluation and develop initiatives to 56 improve asthma diagnosis in the community. 57
We used a longitudinal population-based cohort of individuals with physician-diagnosed 58 asthma to compare total direct asthma-related healthcare costs in patients with a confirmed 59 diagnosis of asthma versus patients in whom a diagnosis of asthma was ruled out using objective 60 tests. Secondary objectives were to characterize differences in healthcare resource use in terms of 61 the 1) number of outpatient physician visits, and 2) type and amount of asthma medication use. 62 63 64
METHODS 65

Study Design and Sample 66
We used longitudinal data from the Economic Burden of Asthma study (University of British 67
Columbia Human Ethics #H10-01542), which has been previously described 11, 12 . In summary, 68 individuals with a self-reported physician diagnosis of asthma and at least one asthma-related 69 healthcare encounter in the past 5 years were eligible for study inclusion. Secondary outcomes were the number of asthma-related outpatient physician visits and 92 use of asthma medications. We did not evaluate asthma-related emergency department visits and 93 hospitalizations as a separate outcome due to the low frequency of these events (N=14). The 94 number of outpatient physician visits over one-year of follow-up was assessed separately by 95 physician type (primary care or specialist). Medication use was captured using the questionnaire 96
shown in e-Appendix 1, and medications were classified into controller or reliever using a 97 reference list (e- Table 1 Average annual direct healthcare costs over one year was $497.9 (SD $677.9) in participants 153 with confirmed asthma and $307.7 (SD $424.1) in those with asthma ruled out. The difference in 154 average annual direct healthcare costs ($190 .2) between exposure groups was significant in the 155 unadjusted analysis (p<0.01, Table 1 ). Average annual direct healthcare costs were 1.6 times 156 (95%CI 1.14-2.22, p=0.01) higher in participants with confirmed asthma after adjustment for 157 participant sex, age, ethnicity, income, insurance coverage, and education (Figure 3) . 158 <<Figure 3>> 159 160
Outpatient Physician Visits 161
Total number of primary care physician visits over one year was similar between participants 162 with confirmed asthma and those with asthma ruled out (2.1 vs. 2.7 visits, p=0.85, Table 1) . 163
However, participants with confirmed asthma visited specialist physicians more often than those 164 who had asthma ruled out (0.6 vs 0.2 visits per year, p=0.02). The adjusted analysis also 165 indicated no significant difference in the number of primary care physician visits between 166 participants with confirmed asthma and those with asthma ruled out (p=0.08, Figure 3) . 167
Confirmed asthma was associated with 2.42 times (95%CI 1.06-5.42, p=0.03) more specialist 168 visits than when asthma diagnosis was ruled out. 169
170
Medication Usage 171
Participants with a confirmed diagnosis of asthma used controller medications for a greater 172 proportion of follow-up time than those with asthma ruled out (MPR of 74.9% vs. 54.0%, 173 p=0.02), and similarly for reliever medications (31.3% vs. 19.5%, p<0.01, Table 1 ). This 174 difference persisted in the adjusted analysis for reliever medications but not for controller 175 medications (p=0.12, Figure 3) . MPR for reliever medications was 1.62 times higher (95%CI 176 1.09-2.34, p=0.01) among participants with confirmed asthma than those with asthma ruled out. 177 178 179
DISCUSSION 180
In this study, we used objective tests to confirm the diagnosis of asthma in a random sample of 181 the general population with a self-reported physician diagnosis of asthma. We found that asthma 182 could be ruled out in 25% of cases. This proportion is in line with previous studies, which 183 estimated a 28-33% rate of overdiagnosis in the general Canadian population 9,10 . We compared 184 direct asthma-related healthcare costs between participants with confirmed asthma versus those 185 with asthma ruled out. Although total direct costs were higher in participants with a confirmed 186 diagnosis of asthma, the costs of misdiagnosed asthma remained substantial. The average direct 187 healthcare costs for a participant with misdiagnosed asthma was $308 over 12 months; $190 188 lower than for participants with a confirmed diagnosis. misdiagnosed asthma patients remain at risk of net harm due to medication side effects 23 , and 211 may be incurring healthcare expenditure without therapeutic benefit. Further, asthma 212 medications may have masked symptoms of a serious underlying illness and resulted in a delay 213 in diagnosis and treatment of the correct disease. We did not evaluate the true underlying 214 condition in this sample, but as an example, two patients in a study by Aaron et al. 9 had 215 subglottic stenosis, which was treated as asthma for a number of years before the correct 216 diagnosis was identified during the study. 217
To our knowledge, this is the first study examining the costs associated with 218 treatments, or to treat the underlying diseases of misdiagnosed patients 25 . Given the prevalence 228 and associated costs of misdiagnosis, our findings highlight the need for objective testing to 229 accompany all new diagnoses of asthma 2, 6 . 230
Strengths of this study include a random sample of the general population, which means 231 our results are likely to be representative of routine healthcare use. We evaluated airway 232 reversibility using objective tests recommended by international guidelines 2, 6 , which allowed us 233 to evaluate the costs of evidence-based practices. Limitations of our study should be recognized. 234
First, our algorithm for ruling out asthma was less rigorous than some previous studies 9, 10, 26 235 because it involved one fewer methacholine challenge test. It is possible that this led to a higher 236 rate of misdiagnosis in our study. Second, we excluded participants in whom an objective 237 diagnostic test was contraindicated due to asthma-related reasons, which may have resulted in 238 lower representation of participants with high resource utilization due to more severe disease. 239
Finally, we did not assess other health conditions that might have been responsible for the 240 misdiagnosis and therefore could not evaluate their cost implications. If ruling out an asthma 241 diagnosis results in the correct alternative diagnosis, the proper management of the underlying 242 condition could confer further benefit; this aspect was not evaluated in our study. 
